~~<i id='18825F9CA3'><strike id='18825F9CA3'><tt id='18825F9CA3'><pre id='18825F9CA3'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：knowledge 2025-10-02 05:06:11 Page View：75

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: What happened with Sarepta's Duchenne data
Next article： As demand for Covid shots wanes, Moderna seeks its next success

focus

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Eli Lilly to pay $200M for Beam’s stake in gene

AdobeEliLillysaidTuesdaythatitwillpay$200milliontogene-editingfirmBeamTherapeuticsforBeam’sstakeinVe

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Emergency medicine has repudiated 'excited delirium.' Now what?

AdobeGeorgeFloyd.AngeloQuinto.ElijahMcClain.Allthreemenwerekilledbylethalforceinflictedbythepolice,a